EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY 4.0

Etirinotecan Pegol ( NKTR ‐102) in Patients With Active Brain Metastases From Lung or Breast Cancer

Seema Nagpal, Kim-Son Nguyen, Sophie Bertrand, Kristen May Cunanan, Sukhmani K Padda, Judy Y Pagtama, Alison Holmes Tisch, Gwen Coffey, Reena P Thomas, George W Sledge, Joshua Gruber, Melinda L Telli und 6 weitere

Cancer Reports · 2025-09 · 8 (9)

DOI: 10.1002/cnr2.70330 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer Reports, online erschienen am 28.08.2025. Verfasst von Seema Nagpal und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Division of Neuro-Oncology, Stanford University, Stanford, California, USA. Hauptthemen laut MEDLINE: Brain Neoplasms, Breast Neoplasms, Lung Neoplasms, Polyethylene Glycols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nektar Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Brain metastases are common in patients with lung and breast cancer and are associated with poor outcomes. While there is some intracranial activity with systemic therapies, most chemotherapies are minimally effective. Etirinotecan pegol (EP) is a PEGylated chemotherapy with favorable pharmacokinetics over irinotecan.

Methods

We conducted a phase 2 trial of EP in patients with previously treated metastatic non‐small cell lung cancer (NSCLC, n = 12), small cell lung cancer (SCLC, N = 3) and breast cancer (MBC, n = 12), having progressive brain metastases after brain‐directed radiotherapy (or refusal). The primary endpoint was a 25% or greater disease control rate, defined as CR, PR+SD, in the central nervous system (CNS) at 12 weeks; secondary endpoints included toxicity and systemic disease control.

Results

The CNS control rate at 12 weeks in NSCLC and MBC was 17% (two patients in each cohort) and 0% in SCLC. The median overall progression‐free survival for NSCLC was 2.7 months (95% CI: 1.3, 6.7) and MBC was 1.4 months (95% CI: 1.3, 6.9). The most common adverse events were diarrhea (48%), nausea (48%) and fatigue (26%). Six patient deaths occurred in this study. Dehydration/diarrhea (1) and neutropenic sepsis (3) from study treatment were at least possibly related to these deaths.

Conclusion

This study demonstrates that EP did not meet the threshold of clinical efficacy in patients with refractory CNS metastases from lung or breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsBreast NeoplasmsLung NeoplasmsPolyethylene GlycolsHeterocyclic Compounds, 4 or More RingsCarcinoma, Non-Small-Cell LungSmall Cell Lung CarcinomaHumansFemaleMiddle AgedAgedMaleAdultProgression-Free Survival

Stichwörter der Autor:innen

NKTR‐102brain metastasesbreast canceretirinotecan pegolnon‐small cell lung cancer (NSCLC)

Substanzen

Polyethylene Glycolsetirinotecan pegolHeterocyclic Compounds, 4 or More Rings

Autor:innen und Institutionen

  • Department of Neurology, Division of Neuro-Oncology, Stanford University, Stanford, California, USA.
  • Department of Medicine, Division of Oncology, Stanford University, Stanford, California, USA.
  • Quantitative Sciences Unit, School of Medicine, Stanford University, Stanford, California, USA.
  • Fox Chase Cancer Center, Temple University, Philadelphia, Pennsylvania, USA.
  • Stanford Health Care, Stanford, California, USA.
  • UT Southwestern Medical Center, Dallas, Texas, USA.

ORCID-Profile: Joel W Neal

Förderung

  • Nektar Therapeutics

Zitieren

APA

Nagpal, S., Nguyen, K. S., Bertrand, S., Cunanan, K. M., Padda, S. K., Pagtama, J. Y., Tisch, A. H., Coffey, G., Thomas, R. P., Sledge, G. W., Gruber, J., Telli, M. L., Pegram, M., Recht, L. D., Wakelee, H. A., Soltys, S. G., Massarweh, S. A., & Neal, J. W. (2025). Etirinotecan Pegol ( NKTR ‐102) in Patients With Active Brain Metastases From Lung or Breast Cancer. Cancer Reports, 8(9). https://doi.org/10.1002/cnr2.70330

Vancouver

Nagpal S, Nguyen KS, Bertrand S, Cunanan KM, Padda SK, Pagtama JY, et al. Etirinotecan Pegol ( NKTR ‐102) in Patients With Active Brain Metastases From Lung or Breast Cancer. Cancer Reports. 2025;8(9). doi:10.1002/cnr2.70330

BibTeX
@article{Nagpal2025,
  author = {Nagpal, Seema and Nguyen, Kim-Son and Bertrand, Sophie and Cunanan, Kristen May and Padda, Sukhmani K and Pagtama, Judy Y and Tisch, Alison Holmes and Coffey, Gwen and Thomas, Reena P and Sledge, George W and Gruber, Joshua and Telli, Melinda L and Pegram, Mark and Recht, Lawrence D and Wakelee, Heather A and Soltys, Scott G and Massarweh, Suleiman A and Neal, Joel W},
  title = {Etirinotecan Pegol ( NKTR ‐102) in Patients With Active Brain Metastases From Lung or Breast Cancer},
  journal = {Cancer Reports},
  year = {2025},
  volume = {8},
  number = {9},
  doi = {10.1002/cnr2.70330}
}
Kostenlos starten →